BlackRock
HZNP

BlackRock’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

BlackRock’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,871,176
Closed -$1.72B – 5564
2023
Q3 		$1.72B Sell
14,871,176
-32,505
-0.2% -$3.49M 0.05% 348
2023
Q2 		$1.53B Sell
14,903,681
-30,807
-0.2% -$3.25M 0.04% 402
2023
Q1 		$1.63B Buy
14,934,488
+139,677
+0.9% +$15.4M 0.05% 371
2022
Q4 		$1.68B Sell
14,794,811
-824,212
-5% -$68.5M 0.05% 350
2022
Q3 		$967M Buy
15,619,023
+1,020,576
+7% +$71.3M 0.03% 504
2022
Q2 		$1.16B Buy
14,598,447
+762,840
+6% +$72.2M 0.04% 457
2022
Q1 		$1.46B Buy
13,835,607
+827,583
+6% +$80.7M 0.04% 450
2021
Q4 		$1.4B Sell
13,008,024
-508,152
-4% -$55.4M 0.04% 476
2021
Q3 		$1.48B Sell
13,516,176
-470,556
-3% -$48.8M 0.04% 442
2021
Q2 		$1.31B Sell
13,986,732
-1,390,437
-9% -$128M 0.04% 486
2021
Q1 		$1.42B Buy
15,377,169
+1,170,191
+8% +$98.7M 0.04% 441
2020
Q4 		$1.04B Buy
14,206,978
+2,653,855
+23% +$197M 0.03% 512
2020
Q3 		$897M Buy
11,553,123
+240,952
+2% +$16.6M 0.03% 497
2020
Q2 		$629M Buy
11,312,171
+1,051,100
+10% +$45M 0.03% 591
2020
Q1 		$304M Sell
10,261,071
-94,388
-0.9% -$3.19M 0.01% 881
2019
Q4 		$375M Sell
10,355,459
-168,742
-2% -$5.17M 0.01% 1020
2019
Q3 		$287M Sell
10,524,201
-855,079
-8% -$22.1M 0.01% 1135
2019
Q2 		$274M Sell
11,379,280
-3,127,233
-22% -$79.3M 0.01% 1195
2019
Q1 		$383M Buy
14,506,513
+609,682
+4% +$14.4M 0.02% 921
2018
Q4 		$272M Buy
13,896,831
+266,698
+2% +$5.23M 0.01% 1074
2018
Q3 		$267M Buy
13,630,133
+178,887
+1% +$3.4M 0.01% 1256
2018
Q2 		$223M Buy
13,451,246
+507,323
+4% +$7.74M 0.01% 1373
2018
Q1 		$184M Sell
12,943,923
-501,630
-4% -$7.41M 0.01% 1426
2017
Q4 		$196M Sell
13,445,553
-163,874
-1% -$2.3M 0.01% 1400
2017
Q3 		$173M Buy
13,609,427
+109,201
+0.8% +$1.39M 0.01% 1473
2017
Q2 		$160M Buy
13,500,226
+239,014
+2% +$2.97M 0.01% 1459
2017
Q1 		$196M Buy
13,261,212
+13,241,875
+68,479% +$214M 0.01% 1314
2016
Q4 		$313K Sell
19,337
-1,481
-7% -$26.9K ﹤0.01% 1896
2016
Q3 		$378K Sell
20,818
-1,526
-7% -$29.8K ﹤0.01% 1854
2016
Q2 		$368K Buy
22,344
+21,042
+1,616% +$340K ﹤0.01% 1795
2016
Q1 		$22K Buy
1,302
+100
+8% +$1.75K ﹤0.01% 2817
2015
Q4 		$26K Buy
1,202
+225
+23% +$4.38K ﹤0.01% 2449
2015
Q3 		$19K Sell
977
-6,621
-87% -$209K ﹤0.01% 2433
2015
Q2 		$264K Buy
+7,598
New +$232K ﹤0.01% 1643
2014
Q3 		– Sell
-1,551
Closed -$25K – 3198
2014
Q2 		$25K Buy
1,551
+108
+7% +$1.54K ﹤0.01% 2273
2014
Q1 		$22K Hold
1,443
– – ﹤0.01% 2322
2013
Q4 		$11K Hold
1,443
– – ﹤0.01% 2683
2013
Q3 		$5K Buy
+1,443
New +$3.81K ﹤0.01% 3010

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

BlackRock's HZNP Position: Q4 2023 in Review

BlackRock sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 14,871,176 shares — an estimated $1.72B sold.

BlackRock first reported a position in HZNP in Q3 2013 and held it in 38 quarters. The position peaked at $1.72B in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • BlackRock reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • BlackRock sold 14,871,176 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.72B.
  • BlackRock first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 38 quarters.
  • BlackRock's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.72B in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on BlackRock's 13F filing for Q4 2023, filed 13 Feb 2024.